| Health Care Equipment & Supplies Industry | Healthcare Sector | Dr. Benjamin J. Lipps CEO | XSTU Exchange | DE000A0HGQF5 ISIN |
| DE Country | 33 Employees | - Last Dividend | - Last Split | - IPO Date |
MagForce AG is a pioneer in the field of nanomedicine, focusing on the development of innovative technologies for the treatment of cancer. Founded in 1997 and based in Berlin, Germany, the company has dedicated itself to creating advanced therapies that offer new hope to patients with solid brain tumors. Utilizing the principles of nanotechnology, MagForce AG is at the forefront of biomedical engineering, striving to improve outcomes and quality of life for those affected by one of the most challenging diseases of our time.
This therapy system is a cutting-edge approach in the treatment of solid brain tumors. It leverages the power of nanomedicine to directly target tumor cells, minimizing damage to surrounding healthy tissues.
A sophisticated software tool, NanoPlan is designed to simulate temperature distributions within the treatment area. This assists physicians in planning and executing the NanoTherm therapy system with greater precision and effectiveness.
NanoTherm is a specially formulated magnetic ferrofluid that plays a central role in MagForce AG's therapy system. When administered into a tumor, these nanoparticles can be activated by an external magnetic field, generating heat to destroy cancer cells.
The NanoActivator is a medical device that produces the magnetic field necessary to activate the NanoTherm particles. It is an essential component of the NanoTherm therapy system, enabling the targeted treatment of tumors.